Moderna heard its results on a call Sunday afternoon with members of the Data Safety and Monitoring Board, an independent panel analyzing Moderna's clinical trial data.
Last week, Pfizer announced its shot was more than 90 percent effective and, on Monday, Moderna announced its jab was 94.5 percent effective. During the trials, 11 people suffered from severe symptoms of COVID-19 but none of them had been immunised.
If the Food and Drug Administration approves the two COVID-19 vaccines, Slaoui said they could reach Americans in December.More news: Moldova election: Pro-EU candidate Sandu leads in preliminary results
BE is making the vaccine in collaboration with Dynavax Technologies Corporation (Dynavax), a US-based vaccine focused biopharmaceutical company, and Baylor College of Medicine, a health sciences university in Houston.
Despite the promising data, Moderna isn't ready to roll out its vaccine in a mass immunization campaign just yet.
Should the two leading vaccines from Pfizer and Moderna achieve success and acquire approval from United States regulators in the coming weeks, Slaoui is confident they will soon apply for emergency use authorization. Once injected, the body's immune system makes antibodies to the spikes.More news: COVID-19 Survivors May Be at Greater Mental Health Risk
Research on mRNA began many years before the current pandemic.
The vaccine was designed with assistance from the National Institute of Allergy and Infectious Diseases' vaccine research center; development of the vaccine has been supported by almost $1 billion in grants from the Biomedical Advanced Research and Development Authority. Both the Moderna and Pfizer shots are frozen but at different temperatures. That would mean some 10 million people could be immunized, as the vaccine must be administered in two doses.
"That 90% might go down a bit as they get more numbers of course, we still don't know if that is the final number, but even if it got to 70% that is still a big success story".
Pfizer's vaccine must be kept at around -94 degrees Fahrenheit - far colder than a typical freezer can accommodate.More news: China's sweeping COVID controls put frozen food importers on ice
A number of vaccination companies are working to increase the supply, he said: "so we could have a normal winter next (year)". "We leverage infrastructure that already exists for other marketed vaccines". Even as the news of Pfizer vaccine which claims to have 90 per cent protection offered hope, it also posed a problem for the governments and health apparatus to store and deploy it as the Pfizer vaccine can not be removed from a temperature of -70 degrees Celsius more than four times.